NO973023L - Fremgangsmåte og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin - Google Patents

Fremgangsmåte og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin

Info

Publication number
NO973023L
NO973023L NO973023A NO973023A NO973023L NO 973023 L NO973023 L NO 973023L NO 973023 A NO973023 A NO 973023A NO 973023 A NO973023 A NO 973023A NO 973023 L NO973023 L NO 973023L
Authority
NO
Norway
Prior art keywords
allergic rhinitis
descarboethoxyloratadine
disorders
preparations
treatment
Prior art date
Application number
NO973023A
Other languages
English (en)
Other versions
NO317555B1 (no
NO973023D0 (no
Inventor
A K Gunnar Aberg
John R Mccullough
Emil R Smith
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23443929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973023(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO973023D0 publication Critical patent/NO973023D0/no
Publication of NO973023L publication Critical patent/NO973023L/no
Publication of NO317555B1 publication Critical patent/NO317555B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19973023A 1994-12-30 1997-06-27 Fremgangsmate og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin NO317555B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,651 US5595997A (en) 1994-12-30 1994-12-30 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
PCT/US1995/015995 WO1996020708A1 (en) 1994-12-30 1995-12-11 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Publications (3)

Publication Number Publication Date
NO973023D0 NO973023D0 (no) 1997-06-27
NO973023L true NO973023L (no) 1997-08-19
NO317555B1 NO317555B1 (no) 2004-11-15

Family

ID=23443929

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19973023A NO317555B1 (no) 1994-12-30 1997-06-27 Fremgangsmate og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin
NO20020211A NO330421B1 (no) 1994-12-30 2002-01-15 Anvendelse av deskarboksyloratadin for fremstilling av et farmasoytisk preparat for behandling av allergisk astma
NO20110077A NO20110077L (no) 1994-12-30 2011-01-18 Anvendelse av deskarboetoksyloratadin for fremstilling av et farmasoytisk preparat for behandling av medisinske tilstander

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20020211A NO330421B1 (no) 1994-12-30 2002-01-15 Anvendelse av deskarboksyloratadin for fremstilling av et farmasoytisk preparat for behandling av allergisk astma
NO20110077A NO20110077L (no) 1994-12-30 2011-01-18 Anvendelse av deskarboetoksyloratadin for fremstilling av et farmasoytisk preparat for behandling av medisinske tilstander

Country Status (21)

Country Link
US (2) US5595997A (no)
EP (3) EP0799037B1 (no)
JP (1) JP4237822B2 (no)
KR (1) KR100442675B1 (no)
CN (2) CN1267098C (no)
AT (1) ATE339956T1 (no)
AU (1) AU707541B2 (no)
BR (1) BR9510129A (no)
CA (1) CA2208836C (no)
CZ (1) CZ293068B6 (no)
DE (2) DE69535234T2 (no)
DK (1) DK0799037T3 (no)
ES (1) ES2144980T3 (no)
FI (1) FI972781L (no)
HU (1) HU229871B1 (no)
MX (1) MX9704793A (no)
NO (3) NO317555B1 (no)
NZ (1) NZ300398A (no)
PT (1) PT799037E (no)
SK (3) SK287257B6 (no)
WO (1) WO1996020708A1 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279684B6 (sk) * 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
SK105698A3 (en) * 1996-02-08 1999-05-07 Merck & Co Inc Method of treatment and pharmaceutical composion
BR9712705A (pt) * 1996-10-31 1999-10-26 Schering Corp Composição para o tratamento da asma, contendo loratadina e um descongestionante
US6324267B1 (en) 1997-01-17 2001-11-27 Scientific-Atlanta, Inc. Two-tiered authorization and authentication for a cable data delivery system
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
HUP0101369A3 (en) * 1997-12-23 2002-11-28 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
DE69919789T2 (de) * 1998-06-30 2005-09-08 Pfizer Products Inc., Groton Loratadin zur Verwendung als Antiarrhythmikum
IL139407A0 (en) 1998-07-10 2001-11-25 Schering Corp 8-CHLORO-6, 11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO [5,6] CYCLOHEPTA [1, 2-b] PYRIDINE ORAL COMPOSITIONS
AU6018899A (en) * 1998-09-10 2000-04-03 Schering Corporation Antihistamines for treating non-infective sinusitis or otitis media
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
AU7704200A (en) * 1999-09-21 2001-04-24 Schering Corporation Treating allergic and inflammatory conditions
CA2383214A1 (en) * 1999-09-22 2001-03-29 Schering Corporation Treating allergic and inflammatory conditions
EP1227812B1 (en) * 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
JP2003518045A (ja) * 1999-12-21 2003-06-03 シェーリング コーポレイション 小児患者におけるアレルギー性状態および炎症性状態の処置のためのデスロラタジンの使用
CN1213752C (zh) * 2000-02-03 2005-08-10 先灵公司 变应性和炎性疾病的治疗
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
EP1267870A2 (en) * 2000-04-07 2003-01-02 Schering Corporation Inhibition of cytokine generation
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
WO2002067938A2 (en) * 2000-10-30 2002-09-06 Schering Corporation Treating or reducing the risk of cardiovascular disease
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
KR20050037405A (ko) * 2001-10-17 2005-04-21 히사미쯔 제약 주식회사 경피 흡수형 제제
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
ATE317268T1 (de) * 2001-12-05 2006-02-15 Alcon Inc Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20030004179A1 (en) * 2002-05-21 2003-01-02 Affrime Melton B Treating allergic and inflammatory conditions
JP2005539010A (ja) * 2002-08-05 2005-12-22 サンド・アクチエンゲゼルシヤフト デスロラタジンヘミフマレートの新規な塩及び多形体
DE60217934T2 (de) * 2002-09-24 2007-05-24 Morepen Laboratories Ltd. Verfahren zur herstellung von desloratadin
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
SK50112007A3 (sk) * 2004-07-07 2007-07-06 Egis Gy�gyszergy�r Nyrt. Nový pseudopolymorf desloratadínu vytvorený s oxidom uhličitým
BRPI0513417A (pt) * 2004-07-16 2008-05-06 Cipla Ltd composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
US20060154948A1 (en) * 2005-01-12 2006-07-13 Schering Corporation Treating allergic and inflammatory conditions
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
CA2653953C (en) 2006-06-01 2015-12-08 Schering-Plough Healthcare Products, Inc. Phenylephrine pharmaceutical formulations and compositions for colonic absorption
EP2120945A1 (en) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamine combination
WO2009020620A1 (en) * 2007-08-06 2009-02-12 Bridge Pharma, Inc. Synergisms between repartitioning and immunomodulating compounds
EP2203169A4 (en) * 2007-09-18 2013-12-04 Stephen Wills GLYCEMIC INSPECTION, DIABETES TREATMENT, AND OTHER TREATMENTS WITH ACETYLCHOLINESTERASE INHIBITORS
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8073632B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
ATE525064T1 (de) 2009-07-01 2011-10-15 Tiefenbacher Alfred E Gmbh & Co Kg Pharmazeutische zusammensetzung mit desloratadin
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
WO1985003707A1 (en) * 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
NZ238629A (en) * 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen

Also Published As

Publication number Publication date
CA2208836C (en) 2001-12-04
DK0799037T3 (da) 2007-02-12
HUT77315A (hu) 1998-03-30
NO20020211D0 (no) 2002-01-15
MX9704793A (es) 1997-10-31
FI972781A7 (fi) 1997-08-27
US5595997A (en) 1997-01-21
ATE339956T1 (de) 2006-10-15
CZ202697A3 (cs) 1998-03-18
EP1078633A3 (en) 2001-03-07
NO317555B1 (no) 2004-11-15
SK88897A3 (en) 1998-02-04
NO973023D0 (no) 1997-06-27
JP4237822B2 (ja) 2009-03-11
KR100442675B1 (ko) 2004-10-14
JPH10512240A (ja) 1998-11-24
ES2144980T1 (es) 2000-07-01
DE69535234T2 (de) 2007-09-13
BR9510129A (pt) 1997-12-30
AU4512696A (en) 1996-07-24
AU707541B2 (en) 1999-07-15
NO20110077L (no) 1997-08-19
EP0799037B1 (en) 2006-09-20
CN1267098C (zh) 2006-08-02
NO330421B1 (no) 2011-04-11
SK287257B6 (sk) 2010-05-07
SK286079B6 (sk) 2008-03-05
FI972781L (fi) 1997-08-27
SK284834B6 (sk) 2005-12-01
DE799037T1 (de) 2000-10-05
NZ300398A (en) 2001-04-27
CA2208836A1 (en) 1996-07-11
FI972781A0 (fi) 1997-06-27
PT799037E (pt) 2006-12-29
EP0799037A1 (en) 1997-10-08
WO1996020708A1 (en) 1996-07-11
NO20020211L (no) 1997-08-19
US5731319A (en) 1998-03-24
CZ293068B6 (cs) 2004-02-18
CN1176598A (zh) 1998-03-18
EP0799037A4 (en) 1998-05-06
CN1935141A (zh) 2007-03-28
CN1935141B (zh) 2013-04-24
HK1008185A1 (en) 1999-05-07
DE69535234D1 (de) 2006-11-02
EP1078633A2 (en) 2001-02-28
HU229871B1 (en) 2014-11-28
EP1712232A1 (en) 2006-10-18
ES2144980T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
NO973023D0 (no) Fremgangsmåte og sammensetninger for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin
NO993847L (no) FremgangsmÕter og preparater for behandling av allergisk astma og andre sykdommer ved anvendelse av deskarboetoksyloratadin
EP0377520A3 (en) Use of nicotine for the manufacture of a kit for the treatment of conditions susceptible to said treatment
IL208184A0 (en) Glp-1, and methods for treating diabetes
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
WO1991004058A3 (en) Treatment of conditions and disease
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
NO307546B1 (no) Farmasøytisk preparat inneholdende optisk ren R-ketorolak samt anvendelse derav
HK1044119A1 (zh) 使用地洛他定治疗睡眠障碍
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
GB9504329D0 (en) Use of norastemizole for the treatment of allergic disorders
SI0652000T1 (en) Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting angiogenisis and angiogenic diseases
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
WO2002076381A3 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
NO893256D0 (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU93008441A (ru) Способ длительной антистрессорной терапии у хирургических больных
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
WO2001039760A3 (en) Method of treating batten disease
Chairman et al. College Of Physicians Of Philadelphia: Section on Ophthalmology
Gale Intranasal sodium cromoglycate(Rynacrom) v. azatadine maleate(Zadine) in the treatment of seasonal allergic rhinitis.
TW207496B (en) Pharmaceutical composition for preventing or delaying the occurrence of dementia

Legal Events

Date Code Title Description
MK1K Patent expired